Zepbound, Foundayo, and Wegovy will be covered
However, results are heterogeneous and strain-specific
complete LOF - to delineate differential treatment responses
The subsequent success of GLP-1 receptor agonists, despite early gastrointestinal intolerance and safety concerns, illustrates how such signals may be manageable through improved formulation and dosing rather than indicative of fundamental biological unsuitability
Building healthy behaviors Regardless of whether your employees use GLP-1s for weight loss or not, its important to remember that for consistent progress, long-term behavior changes are key
It is not licensed by the MHRA in the UK for any indication, and evidence supporting its use in the general population for weight management or body composition purposes is limited